BrightPath to receive non-exclusive rights to Artisan’s STAR-CRISPR editing platform to accelerate development of BrightPath’s invariant natural killer T (iNKT) cells Artisan to receive an upfront payment and research milestones, plus license fees, development milestones, net sales…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.